You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

CLINICAL TRIALS PROFILE FOR SHR6390

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for SHR6390

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02671513 ↗	A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients	Unknown status	Beijing Cancer Hospital	Phase 1	SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.
NCT02671513 ↗	A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients	Unknown status	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.
NCT02684266 ↗	A Study of SHR6390 in Advanced Solid Tumor Patients	Unknown status	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.
NCT03480256 ↗	Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer	Unknown status	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
NCT03480256 ↗	Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer	Unknown status	Peking University	Phase 1	The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for SHR6390

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Breast Cancer	12
Advanced Breast Cancer	6
Metastatic Breast Cancer	5
Healthy Volunteers	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Breast Neoplasms	26
Carcinoma	2
Carcinoma, Squamous Cell	1
Renal Insufficiency	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SHR6390

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	32
Australia	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SHR6390

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	3
Phase 2	17
[disabled in preview]	21
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Not yet recruiting	20
Recruiting	8
Completed	6
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SHR6390

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Jiangsu HengRui Medicine Co., Ltd.	26
Fudan University	6
Tianjin Medical University Cancer Institute and Hospital	4
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	28
Other	27
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.